Bhumi J. Bhatt

Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The authors have nothing to report. References 1, , and , “Global Burden of Female Breast Cancer: New Estimates in 2022, Temporal Trend and Future Projections up to 2050 Based on the Latest Release From GLOBOCAN,” Journal of the National Cancer Center 5, no. 3 (2025): 287–296, https://doi.org/10.1016/j.jncc.2025.02.002.

1 Introduction It is increasingly recognized that drugs used to treat tumours also exert deleterious effects on muscle [1]. Myotoxicity is now considered to be one of the negative effects of systemic treatments impairing muscle function, compromising treatment response and escalating toxicities [2].

Abstract Cancer-associated muscle wasting is associated with poor clinical outcomes1, but its underlying biology is largely uncharted in humans2. Unbiased analysis of the RNAome (coding and non-coding RNAs) with unsupervised clustering using integrative non-negative matrix factorization3 provides a means of identifying distinct molecular subtypes and was applied here to muscle of patients with colorectal or pancreatic cancer.